<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02068482</url>
  </required_header>
  <id_info>
    <org_study_id>MDSNC2009</org_study_id>
    <nct_id>NCT02068482</nct_id>
  </id_info>
  <brief_title>Immunohistology in USDD and Correlation Between Bacterial Flora and Phlogosis</brief_title>
  <official_title>Evaluation of Immunohistological Pattern in Patients With Uncomplicated Symptomatic Diverticular Disease and Correlation Between Intraluminal Bacterial Flora and Phlogosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diverticulosis of the colon is a frequent condition in adults in western countries and a
      significant number of patients experience clinical symptoms even when the diverticulosis is
      not complicated by diverticulitis.

      Both central and mucosal immunity are altered in Uncomplicated Symptomatic Diverticular
      Disease (USDD) and Rifaximin ameliorate clinical symptoms and normalize the immunological
      abnormalities.

      The Study Protocol is verify the modifications in the immunological pattern induced by
      reducing bacteria related activation of immunity by Rifaximin treatment.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">May 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunohistological Pattern</measure>
    <time_frame>Two months</time_frame>
    <description>Lymphocytes in peripheral Blood, Lymphocytes in the Sigmoid Mucosa, Lymphocytes in the Transverse Mucosa, Monocytes and Granulocytes in Peripheral Blood</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical Symptoms</measure>
    <time_frame>Two Months</time_frame>
    <description>Dyspepsia, Meteorism, Abdominal pain, Tenesmus, Diarrhea, Fever, Fever with Chills, Painful Palpation, VAS, Likert, Numbers of Evacuations</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">61</enrollment>
  <condition>Diverticular Disease</condition>
  <arm_group>
    <arm_group_label>1a USDD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>1b USDD</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients control, no drug</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Control Group, no disease, no drug</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rifaximin</intervention_name>
    <description>Rifaximin 200 mg 6 tbs per day per 15 days/ month for 2 months</description>
    <arm_group_label>1a USDD</arm_group_label>
    <other_name>Normix</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  male and female

          -  age 18 or more

          -  radiologic or endoscopic diagnosis of diverticular disease located in sigma or colon
             descendent

          -  Informed consent

          -  patients willing to participate in to the study

        Exclusion Criteria:

          -  other colon diseases

          -  Inflammatory Bowel Diseases

          -  signs or symptoms of inflammation

          -  consumption of : antibiotics, anti-inflammatory drugs ( FANS and 5-ASA), prebiotics,
             Proton Pump Inhibitors, corticosteroids, fiber within three months

          -  pregnancy and breast feeding

          -  acute diverticulitis characterized by:

          -  moderate/sever pain in left iliac fossa

          -  fever &gt; 38Â°C

          -  abdominal pain

          -  haematochezia

          -  leukocytosis (20% more than the normal range)

          -  remote acute diverticulitis

          -  rifaximin hypersensitivity

          -  neoplastic diseases

          -  immunodeficiencies

          -  poor physical conditions

          -  leaver deficiencies (Child C), kidney (Creatinine&gt;2,2 mg/dl), heart (NYHA 3-4)

          -  major psychiatric illness

          -  drugs abuses and alcoholism

          -  participations in other clinical trials within 4 weeks

          -  patients unwillingness certificate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franco Pandolfi, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>CU Sacred Heart</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lucio Petruzziello, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>CU Sacred Heart</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paola Cesaro, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>CU Sacred Heart</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rossella Cianci, Doctor</last_name>
    <role>Study Chair</role>
    <affiliation>CU Sacred Heart</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cattholic University of the Sacre Heart</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 12, 2014</study_first_submitted>
  <study_first_submitted_qc>February 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 21, 2014</study_first_posted>
  <last_update_submitted>February 19, 2014</last_update_submitted>
  <last_update_submitted_qc>February 19, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 21, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Guido Costamagna</investigator_full_name>
    <investigator_title>Director of Digestive and Surgical Endoscopy</investigator_title>
  </responsible_party>
  <keyword>Uncomplicated</keyword>
  <keyword>Symptomatic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diverticulum</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rifaximin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

